PROSTATIC NEOPLASMS
Clinical trials for PROSTATIC NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new PROSTATIC NEOPLASMS trials appear
Sign up with your email to follow new studies for PROSTATIC NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Vaccine trial halted early in fight against prostate cancer return
Disease control TerminatedThis study tested an experimental vaccine called PROSTVAC-V/F to see if it could stop prostate cancer from coming back after surgery in men at high risk of relapse. The trial was terminated early and enrolled only 33 participants before ending. Researchers aimed to measure how lo…
Matched conditions: PROSTATIC NEOPLASMS
Phase: PHASE2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Drug combo test halted early for business reasons
Disease control TerminatedThis study aimed to see if combining two drugs, cabozantinib and abiraterone, was safe and effective for men with advanced prostate cancer that had spread to their bones and was no longer responding to standard hormone therapy. Participants were assigned to receive different dose…
Matched conditions: PROSTATIC NEOPLASMS
Phase: PHASE2 • Sponsor: Exelixis • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Can a video game train surgeons to fight prostate cancer?
Knowledge-focused TerminatedThis study aimed to see if an online video simulator helps surgeons learn a complex prostate cancer removal surgery. It compared surgeons trained with the simulator to those using standard training methods. The goal was to see if the simulator led to faster, safer surgeries with …
Matched conditions: PROSTATIC NEOPLASMS
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Mar 25, 2026 14:08 UTC
-
Blood test could predict prostate cancer drug success
Knowledge-focused TerminatedThis study aimed to see if measuring a specific protein in the blood (called uPAR) could help predict which men with advanced prostate cancer would respond well to the drug abiraterone. It involved a very small group of patients whose cancer had progressed despite other treatment…
Matched conditions: PROSTATIC NEOPLASMS
Sponsor: Kristoffer Rohrberg • Aim: Knowledge-focused
Last updated Mar 24, 2026 12:03 UTC